Jason Bobe blogs at The Personal Genome about this concept of presidential candidates providing genetic information as part of the campaign process. He cites an article from New England Journal of Medicine in which authors Robert Green and George Annas "advocate for the next presidential candidates to honor a 'Don't Ask, Don't Tell' policy for DNA," Bobe writes. He says that in four years, the public will be "radically more conversant in and curious about DNA." But does that mean genetic data should be disclosed? "Could you imagine scenarios where genetic information might influence your decision to vote for one candidate over another?" Bobe asks. In another perspective on personalized medicine, Gary Marchant, Robert Milligan, and Brian Wilhelmi have a paper in Future Medicine on legal liability issues they see arising in lock-step with advances in pharmacogenomics and other tailored approaches to medicine. Acknowledging that there's no way to predict exactly what will happen, they write, "It is clear that pharmaceutical manufacturers, healthcare providers and others may be subjected to significant liability for failure to adequately implement pharmacogenomic technologies."
Premium Trial: